S&P 500   3,252.27 (-1.75%)
DOW   26,296.94 (-1.36%)
QQQ   268.43 (-2.88%)
AAPL   109.31 (-5.21%)
MSFT   199.96 (-2.33%)
FB   261.54 (-6.87%)
GOOGL   1,619.09 (+4.00%)
AMZN   3,062.43 (-4.63%)
TSLA   386.46 (-5.93%)
NVDA   496.94 (-4.61%)
BABA   301.45 (-3.55%)
CGC   18.20 (-3.09%)
GE   7.35 (-0.27%)
MU   49.63 (-1.68%)
AMD   74.94 (-3.95%)
T   26.81 (+0.19%)
F   7.71 (-2.41%)
ACB   3.91 (-4.40%)
GILD   57.26 (-2.17%)
NIO   30.49 (-4.69%)
NFLX   478.17 (-5.16%)
BA   143.27 (-3.39%)
DIS   119.46 (-1.71%)
S&P 500   3,252.27 (-1.75%)
DOW   26,296.94 (-1.36%)
QQQ   268.43 (-2.88%)
AAPL   109.31 (-5.21%)
MSFT   199.96 (-2.33%)
FB   261.54 (-6.87%)
GOOGL   1,619.09 (+4.00%)
AMZN   3,062.43 (-4.63%)
TSLA   386.46 (-5.93%)
NVDA   496.94 (-4.61%)
BABA   301.45 (-3.55%)
CGC   18.20 (-3.09%)
GE   7.35 (-0.27%)
MU   49.63 (-1.68%)
AMD   74.94 (-3.95%)
T   26.81 (+0.19%)
F   7.71 (-2.41%)
ACB   3.91 (-4.40%)
GILD   57.26 (-2.17%)
NIO   30.49 (-4.69%)
NFLX   478.17 (-5.16%)
BA   143.27 (-3.39%)
DIS   119.46 (-1.71%)
S&P 500   3,252.27 (-1.75%)
DOW   26,296.94 (-1.36%)
QQQ   268.43 (-2.88%)
AAPL   109.31 (-5.21%)
MSFT   199.96 (-2.33%)
FB   261.54 (-6.87%)
GOOGL   1,619.09 (+4.00%)
AMZN   3,062.43 (-4.63%)
TSLA   386.46 (-5.93%)
NVDA   496.94 (-4.61%)
BABA   301.45 (-3.55%)
CGC   18.20 (-3.09%)
GE   7.35 (-0.27%)
MU   49.63 (-1.68%)
AMD   74.94 (-3.95%)
T   26.81 (+0.19%)
F   7.71 (-2.41%)
ACB   3.91 (-4.40%)
GILD   57.26 (-2.17%)
NIO   30.49 (-4.69%)
NFLX   478.17 (-5.16%)
BA   143.27 (-3.39%)
DIS   119.46 (-1.71%)
S&P 500   3,252.27 (-1.75%)
DOW   26,296.94 (-1.36%)
QQQ   268.43 (-2.88%)
AAPL   109.31 (-5.21%)
MSFT   199.96 (-2.33%)
FB   261.54 (-6.87%)
GOOGL   1,619.09 (+4.00%)
AMZN   3,062.43 (-4.63%)
TSLA   386.46 (-5.93%)
NVDA   496.94 (-4.61%)
BABA   301.45 (-3.55%)
CGC   18.20 (-3.09%)
GE   7.35 (-0.27%)
MU   49.63 (-1.68%)
AMD   74.94 (-3.95%)
T   26.81 (+0.19%)
F   7.71 (-2.41%)
ACB   3.91 (-4.40%)
GILD   57.26 (-2.17%)
NIO   30.49 (-4.69%)
NFLX   478.17 (-5.16%)
BA   143.27 (-3.39%)
DIS   119.46 (-1.71%)
Log in
NASDAQ:AMGN

Amgen Stock Forecast, Price & News

Trending Stocks   Most-Downgraded Stocks  
$214.37
-3.45 (-1.58 %)
(As of 10/30/2020 11:39 AM ET)
Add
Compare
Today's Range
$213.91
Now: $214.37▼
$216.79
50-Day Range
$216.38
MA: $240.73▼
$257.67
52-Week Range
$177.05
Now: $214.37▼
$264.97
Volume37,459 shs
Average Volume2.87 million shs
Market Capitalization$125.56 billion
P/E Ratio17.51
Dividend Yield2.96%
Beta0.81
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
Amgen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
CIK318154
Webwww.amgen.com
Phone805-447-1000
Employees23,400

Debt

Debt-to-Equity Ratio3.20
Current Ratio2.18
Quick Ratio1.81

Price-To-Earnings

Trailing P/E Ratio17.51
Forward P/E Ratio13.70
P/E Growth2.01

Sales & Book Value

Annual Sales$23.36 billion
Price / Sales5.37
Cash Flow$17.83 per share
Price / Cash Flow12.02
Book Value$16.28 per share
Price / Book13.17

Profitability

EPS (Most Recent Fiscal Year)$14.82
Net Income$7.84 billion
Net Margins30.04%
Return on Equity91.98%
Return on Assets15.24%

Miscellaneous

Outstanding Shares585,694,000
Market Cap$125.56 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$214.37
-3.45 (-1.58 %)
(As of 10/30/2020 11:39 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by Coronavirus (COVID-19)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 8.2% and is now trading at $214.88.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Amgen?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its earnings results on Sunday, November, 1st. The medical research company reported $4.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.75 by $0.62. Amgen had a return on equity of 91.98% and a net margin of 30.04%.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, October 21st. Stockholders of record on Monday, November 16th will be given a dividend of $1.60 per share on Tuesday, December 8th. This represents a $6.40 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend is Friday, November 13th.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

What price target have analysts set for AMGN?

28 equities research analysts have issued 1-year price targets for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they anticipate Amgen's share price to reach $254.12 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price.
View analysts' price targets for Amgen.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 57, Pay $5.61M)
  • Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 59, Pay $2.44M)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 57, Pay $2.54M)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 53, Pay $2.66M)
  • Mr. Peter H. Griffith, Exec. VP & CFO (Age 61)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (0.47%), Candriam Luxembourg S.C.A. (0.22%), DekaBank Deutsche Girozentrale (0.17%), Railway Pension Investments Ltd (0.13%), Robeco Institutional Asset Management B.V. (0.12%) and Envestnet Asset Management Inc. (0.09%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, LSV Asset Management, Cardinal Capital Management Inc., Robeco Institutional Asset Management B.V., Toronto Dominion Bank, Capital Investment Advisors LLC, Artemis Investment Management LLP, and Wedge Capital Management L L P NC. Company insiders that have sold Amgen company stock in the last year include David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

Which major investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., Boston Trust Walden Corp, Sumitomo Mitsui DS Asset Management Company Ltd, Steel Peak Wealth Management LLC, Railway Pension Investments Ltd, State of Alaska Department of Revenue, and Contravisory Investment Management Inc..
View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $214.88.

How big of a company is Amgen?

Amgen has a market capitalization of $125.85 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.